We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Improved Nanoparticles Designed to Deliver Drugs into Brain

By LabMedica International staff writers
Posted on 25 Sep 2012
Scientists have reported they are closer to having a drug-delivery system adaptable enough to overcome some major challenges posed by brain cancer and possibly other disorders affecting that organ.

In a report published online on August 29, 2012, in the journal Science Translational Medicine, the Johns Hopkins University (JHU; Baltimore, MD, USA) investigators reported that its bioengineers have devised nanoparticles that can safely and predictably infiltrate deep into the brain when evaluated in lab rat and human tissue.

“We are pleased to have found a way to prevent drug-embedded particles from sticking to their surroundings so that they can spread once they are in the brain,” said Justin Hanes, PhD, a professor of ophthalmology, with secondary appointments in chemical and biomolecular engineering, biomedical engineering, oncology, neurological surgery, and environmental health sciences, and director of the Johns Hopkins Center for Nanomedicine.

After surgery to remove a brain tumor, standard treatment protocols include the application of chemotherapy directly to the surgical site to destroy any cells left behind that could not be surgically removed. More...
Up to now, this technique of preventing tumor recurrence is only somewhat effective, in part, because it is difficult to administer a dose of chemotherapy high enough to adequately penetrate the tissue to be effective and low enough to be safe for the patient and healthy tissue.

To overcome this dosage challenge, engineers designed nanoparticles--about one-thousandth the diameter of a human hair--that deliver the drug in small, gradual quantities over a period of time. Traditional drug-delivery nanoparticles are made by entrapping drug molecules together with microscopic, string-like molecules in a tight ball, which slowly breaks down when it comes in contact with water. According to Charles Eberhart, MD, a Johns Hopkins pathologist and contributor to this work, these nanoparticles historically have not worked very well because they stick to cells at the application site and tend to not migrate deeper into the tissue.

Elizabeth Nance, a graduate student in chemical and biomolecular engineering at Hopkins, and Hopkins neurosurgeon Graeme Woodworth, MD, suspected that drug penetration might be improved if drug-delivery nanoparticles interacted minimally with their environment. Ms. Nance first coated nanosized plastic beads with a clinically tested molecule called PEG (polyethyleneglycol), that had been shown by others to protect nanoparticles from the body’s defense mechanisms. The team thought that a dense layer of PEG might also make the beads more slippery.

The researchers then injected the coated beads into slices of rodent and human brain tissue. They first labeled the beads with glowing tags that enabled them to visualize the beads as they moved through the tissue. Compared to non-PEG-coated beads, or beads with a less dense PEG coating, they found that a dense coating of PEG allowed larger beads to penetrate the tissue, even those beads that were nearly twice the size earlier believed to be the maximum possible for penetration within the brain. They then tested these beads in live rodent brains and found the same results.

The researchers then took biodegradable nanoparticles carrying the chemotherapy drug paclitaxel and coated them with PEG. As expected, in rat brain tissue, nanoparticles without the PEG coating moved very little, while PEG-covered nanoparticles distributed themselves quite well.

“It’s really exciting that we now have particles that can carry five times more drug, release it for three times as long and penetrate farther into the brain than before,” said Ms. Nance. “The next step is to see if we can slow tumor growth or recurrence in rodents.”

Dr. Woodworth added that the team “also wants to optimize the particles and pair them with drugs to treat other brain diseases, like multiple sclerosis, stroke, traumatic brain injury, Alzheimer’s and Parkinson’s.”

Another objective for the investigators is to be able to administer their nanoparticles intravenously, for which research has already begun.

Related Links:
Johns Hopkins University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
POC Immunoassay Analyzer
Procise DX
Automatic CLIA Analyzer
Shine i6000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: 123RF

Screening After Pneumococcal Disease May Reveal Undiagnosed Blood Cancer or Immune Disorders

Severe pneumococcal disease requiring hospitalization often presents as pneumonia, particularly in older adults and people with cancer or compromised immune function. Because M protein testing and antibody... Read more

Microbiology

view channel
Image Credit: 123RF

FDA-Cleared Multiplex PCR Test Detects 13 Respiratory Pathogens in a Single Sample

Respiratory tract infections can be difficult to distinguish at presentation because many cause overlapping, nonspecific symptoms and are initially grouped as influenza-like illnesses. Causes span a range... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.